New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects
Authors
Keywords
-
Journal
Frontiers in Physiology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-02-10
DOI
10.3389/fphys.2021.603910
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly
- (2020) Mikaël Croyal et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
- (2020) Vera A. Bittner et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
- (2020) Sotirios Tsimikas et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)
- (2020) Gerald F. Watts et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy
- (2020) Prakash Deedwania et al. JAMA Cardiology
- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
- (2019) Kausik K Ray et al. Lancet Diabetes & Endocrinology
- Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects
- (2019) Marja-Riitta Taskinen et al. Journal of Clinical Lipidology
- Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein MetabolismHighlights
- (2018) Dick C. Chan et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate
- (2018) Mikaël Croyal et al. CLINICAL SCIENCE
- Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics
- (2018) Gerald F Watts et al. EUROPEAN HEART JOURNAL
- PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle?
- (2018) Angela Pirillo et al. EUROPEAN HEART JOURNAL
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response
- (2017) Teik Chye Ooi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and StrokeCLINICAL PERSPECTIVE
- (2017) Shia T. Kent et al. Circulation-Cardiovascular Genetics
- PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia
- (2016) Rodrigo Alonso et al. ATHEROSCLEROSIS
- Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy HumansClinical Perspective
- (2016) Gissette Reyes-Soffer et al. CIRCULATION
- Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein MetabolismClinical Perspective
- (2016) Gerald F. Watts et al. CIRCULATION
- Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations
- (2016) Hayato Tada et al. CIRCULATION JOURNAL
- PCSK9 Association With Lipoprotein(a)Novelty and Significance
- (2016) Hagai Tavori et al. CIRCULATION RESEARCH
- PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis
- (2016) Anne Langsted et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- LIPOPROTEIN(A) IN FAMILIAL HYPERCHOLESTEROLEMIA WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
- (2016) Hayato Tada et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state
- (2015) Dick C. Chan et al. CLINICAL SCIENCE
- Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
- (2015) Rocco Romagnuolo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both
- (2015) Brian A. Ference et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Loss- and Gain-of-function PCSK9 Variants
- (2012) Suzanne Benjannet et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The PCSK9 decade
- (2012) Gilles Lambert et al. JOURNAL OF LIPID RESEARCH
- Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people
- (2011) Shelby Sullivan et al. Translational Research
- PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia
- (2009) Bertrand Cariou et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
- (2009) Cédric Le May et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Triglyceride-Rich Lipoproteins and Plasma Lipid Transport
- (2009) Richard J. Havel ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Plasma Proprotein Convertase Subtilisin/Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism?
- (2009) D. C. Chan et al. CLINICAL CHEMISTRY
- PCSK9 function and physiology,: Fig. 1.
- (2008) Andrew S. Peterson et al. JOURNAL OF LIPID RESEARCH
- PCSK9: a convertase that coordinates LDL catabolism
- (2008) Jay D. Horton et al. JOURNAL OF LIPID RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search